Denali Therapeutics (DNLI) - Stock Price & Dividends

Denali Therapeutics Inc. is a biopharmaceutical company listed on NASDAQ under the ticker symbol DNLI. The company is focused on developing a range of innovative product candidates designed to effectively cross the blood-brain barrier to target neurodegenerative diseases and lysosomal storage diseases.

The unique approach of Denali Therapeutics involves evaluating genetically validated targets, developing methods for efficient delivery across the blood-brain barrier, and utilizing biomarkers to gauge target and pathway engagement. Some of the notable transport vehicle (TV)-enabled programs in their pipeline include DNL310 ETV for MPS II, TAK-594/DNL593 for frontotemporal dementia-granulin, DNL126 for MPS IIIA, and DNL622 for MPS I. Additionally, the company is working on preclinical programs that focus on amyloid beta and HER2.

Furthermore, Denali Therapeutics is actively pursuing brain-penetrant small molecule programs such as BIIB122/DNL151 for Parkinson's disease, SAR443820/DNL788 for CNS disease, and DNL343 for amyotrophic lateral sclerosis. They also have ongoing programs like SAR443122/DNL758 for peripheral inflammatory diseases.

The company has established collaboration agreements with several key industry players including Biogen, Genzyme Corporation, Takeda Pharmaceutical, and Genentech. Originally known as SPR Pharma Inc., Denali Therapeutics officially changed its name in 2015 and has been operating since its incorporation in 2013. The company is headquartered in South San Francisco, California. For more information, visit their official website at https://www.denalitherapeutics.com.